Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.
Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA. Harrington KJ, et al. Among authors: vidal l. Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18. Clin Cancer Res. 2010. PMID: 20484020 Free PMC article. Clinical Trial.
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.
Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ. Twigger K, et al. Among authors: vidal l. Clin Cancer Res. 2008 Feb 1;14(3):912-23. doi: 10.1158/1078-0432.CCR-07-1400. Clin Cancer Res. 2008. PMID: 18245555
Making sense of antisense.
Vidal L, Blagden S, Attard G, de Bono J. Vidal L, et al. Eur J Cancer. 2005 Dec;41(18):2812-8. doi: 10.1016/j.ejca.2005.06.029. Epub 2005 Nov 9. Eur J Cancer. 2005. PMID: 16289851 Review.
Reversing resistance to targeted therapy.
Vidal L, Attard G, Kaye S, De Bono J. Vidal L, et al. J Chemother. 2004 Nov;16 Suppl 4:7-12. doi: 10.1179/joc.2004.16.Supplement-1.7. J Chemother. 2004. PMID: 15688600 Review.
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W. Greystoke A, et al. Among authors: vidal l. Ann Oncol. 2006 Aug;17(8):1313-9. doi: 10.1093/annonc/mdl097. Epub 2006 May 25. Ann Oncol. 2006. PMID: 16728482 Free article. Clinical Trial.
671 results